SCHEMBL4311301

SCHEMBL4311301

O=C(O)c1cc2cc(OCc3ccccn3)ccc2[nH]1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.71
SRD5A2 P31213 3/20 0.71
HPGD P15428 2/20 0.71
HSD17B10 Q99714 2/20 0.71
CYP1A2 P05177 2/20 0.71
CYP2C9 P11712 2/20 0.71
ALDH1A1 P00352 1/20 0.71
KMT2A Q03164 2/20 0.59
PDGFRB P09619 3/20 0.57
PDGFRA P16234 3/20 0.57
CFD P00746 1/20 0.55
IDO1 P14902 1/20 0.52
FLT3 P36888 2/20 0.51
DHODH Q02127 1/20 0.50
PARP10 Q53GL7 1/20 0.49
SMAD3 P84022 1/20 0.49
MAPT P10636 2/20 0.48
DAO P14920 1/20 0.48
SRD5A1 P18405 1/20 0.47
PLA2G4A P47712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4314106 0.87 XDH (0.61) KDM4ESRD5A2HPGDHSD17B10CYP1A2
SCHEMBL630515 0.83 SRD5A2 (1.00) KDM4ESRD5A2HPGDHSD17B10CYP1A2
SCHEMBL4466624 0.81 KDM4E (0.61) KDM4ESRD5A2HPGDHSD17B10CYP1A2
SCHEMBL9816433 0.79 KDM4E (0.73) KDM4ESRD5A2HPGDHSD17B10CYP1A2
SCHEMBL7246467 0.79 KDM4E (0.73) KDM4ESRD5A2HPGDHSD17B10CYP1A2
SCHEMBL4465748 0.78 KDM4E (0.58) KDM4ESRD5A2HPGDHSD17B10CYP1A2
SCHEMBL7246655 0.78 KDM4E (0.71) KDM4ESRD5A2HPGDHSD17B10CYP1A2
SCHEMBL6542663 0.77 KDM4E (0.69) KDM4ESRD5A2HPGDHSD17B10CYP1A2
SCHEMBL7244398 0.76 KDM4E (0.68) KDM4ESRD5A2HPGDHSD17B10CYP1A2
SCHEMBL4371734 0.76 PDGFRB (0.71) KDM4ESRD5A2HPGDHSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566781-B2 Imidazopyridine compound BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-07-28 US disclosed
US-7531668-B2 2-arylcarboxamide-nitrogenous heterocycle compound BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-05-12 US disclosed
US-20070299070-A1 2-Arylcarboxamide-Nitrogenous Heterocycle Compound MSD K.K. (JP) 2007-12-27 US disclosed
US-20070249659-A1 melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide BANYU PHARMACEUTICAL., LTD. (JP) 2007-10-25 US disclosed
EP-1798221-A1 2-ARYLCARBOXAMIDE-NITROGENEOUS HETEROCYCLE COMPOUND BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-06-20 EP disclosed
CN-1950372-A imidazopyridine compounds BANYU PHARMA CO LTD (JP) 2007-04-18 CN disclosed
EP-1748048-A1 IMIDAZOPYRIDINE COMPOUND BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249659-A1 melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide MC1R, MCHR2, MCHR1 KDM4E 1794/4885SRD5A2 249/4885HPGD 1131/4885
US-20070299070-A1 2-Arylcarboxamide-Nitrogenous Heterocycle Compound MCHR2, MCHR1, NPY2R KDM4E 2454/4885SRD5A2 430/4885HPGD 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.